BREAST CANCER

A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.

An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with “good risk” DCIS treated without radiation therapy.

In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.

Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive or HER2-negative.

Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic breast cancer.

A study of 9,146 patients found no OS difference among first-line CDK4/6 inhibitor combinations for HR+/HER2- metastatic breast cancer, presented at SABCS 2024.

Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen receptor-positive/HER2-negative metastatic breast cancer treatment.

In the phase 2 SOLTI VALENTINE trial, patritumab deruxtecan with or without letrozole showed similar efficacy to multiagent chemotherapy in HR-positive, HER2-negative breast cancer with fewer severe adverse events.

T-DXd improves progression-free survival vs physician’s choice, regardless of time to progression or endocrine resistance, in HR-positive, HER2-low/-ultralow metastatic breast cancer.

Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

Immediate surgery significantly lowered local recurrence rates in elderly patients with breast cancer compared with delayed surgery, according to a meta-analysis presented at SABCS 2024.

A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial.

Erika P. Hamilton, MD, discusses antibody-drug conjugates in multiple types of breast cancer, and when to use these drugs in sequence.

During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.

Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with lasofoxifene.

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.

Providers advised to halt use, monitor patients, and report any complications with BioZorb devices to the FDA.

In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the results from the phase 3 KEYNOTE-522 trial.

Holly Pederson, MD, and Elisha Hughes, MD, discussed the use of a polygenic risk score to identify why Black women incur higher rates of triple-negative breast cancer at younger ages.

DeepHRD predicted homologous recombination deficiency with greater accuracy than FDA-approved standard molecular tests.

Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.

Following discussions on ado-trastuzumab emtansine and fam-trastuzumab deruxtecan-nxki, Tanya Gupta, MD, discusses sacituzumab govitecan and its approval from the FDA in the breast cancer space.

Tanya Gupta, MD, discusses the use of ado-trastuzumab emtansine for the treatment of patients with HER2-positive breast cancer.

During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.